Ovarian cancer is the seventh most common gynaecologic malignancy seen in women.
Majority of the patients with ovarian cancer are diagnosed at the advanced stage making …

Malignant ascites presents a considerable clinical challenge to the management of ovarian
cancer, but also provides a wealth of opportunities for translational research. The …

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the
United States and is the country's fifth most common cause of cancer mortality in women. A …

Background Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, has previously
shown efficacy in a phase 2 study when given in capsule formulation to all-comer patients …

Background Angiogenesis plays a role in the biology of ovarian cancer. We examined the
effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women …

BACKGROUND: Primary surgery followed by platinum‐taxane based chemotherapy has
been the standard therapy in advanced ovarian cancer. However, the prognostic role of …

Objective To quantify the impact of complete cytoreduction to no gross residual disease on
overall survival among patients with advanced-stage ovarian cancer treated during the …

Background Paclitaxel and carboplatin given every 3 weeks is standard treatment for
advanced ovarian carcinoma. Attempts to improve patient survival by including other drugs …

Purpose To determine if incorporation of an additional cytotoxic agent improves overall
survival (OS) and progression-free survival (PFS) for women with advanced-stage epithelial …

Background Despite recent progress in the treatment of ovarian cancer, the majority of
patients eventually relapse. There is little information on the effectiveness of chemotherapy …